. 2021 Mar 3;2(1):69–80. doi: 10.1530/RAF-20-0057
This work is licensed under a Table 1.
Characterisation of studies.
| Reference | Design | Cohort studied | Average age (years) | Parity | Setting | Study size and attrition | EM location | EM stages | Prev. treatment | Operative approach | Hist. confirm. | Follow-up time from baseline, y | Pre- and post-operative outcome measures | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LAP‡ | EM | Follow-up | |||||||||||||
| Abbott et al. (2003) | POC | ES 1–4 | 31 (20–48) | 0: 80/175 (60%) | 2 UK UH | 261 | 176 | 135 | OE: 38%; USL 88% | Stage 1: 28%; Stage 2: 28%; Stage 3: 17%; Stage 4: 41% | Analgesia: 70%; HT: 70% Prev. LAP: 70% | CLET: 100% | Yes | 5 (3.2 (2–5)⁑) | VAS (10 cm) presented as median and IQR for dysmenorrhoea, dyspareunia, non-menstrual PP, dyschezia) |
| Chopin et al. (2005) | ROC | DE† | 31.7 ± 5.4 | 0.3 ± 0.61 (0–3) | 1 French UAH | 241 | 241 | 132 | USL: 59.9%; vagina: 18.9%; bladder: 9.8%; intenstine: 12.1%; multiple locations: 39.4% | Stage 1: 20.5%; Stage 2: 34.1%; Stage 3: 24.2%; Stage 4: 21.2% | HT: 56%; Prev. LAP: 0.9 ± 1 | CLET: 87.1%; LT: 12.9% | Yes | 3.7 ± 2.0 (median: 3.3) | VAS (10 cm) for each pain type (dysmenorrhoea, dyspareunia, CPP, dyschezia, lower urinary tract symptoms) |
| Banerjee et al. (2006) | POC | ES 1–4 and no EM | NS | 1 UK tertiary EM centre in DGH | 108 | 88 | 46 | OE: 14%; USL: 59%; recto-vaginal: 43%; pouch of Douglas: 43%; intestine: 47% | Stage 1: 39%; Stage 2: 16%; Stage 3: 9%; Stage 4: 36% | NS | CLET: 100% | Yes | 18 months post-surgery | Pre- and post-operative global pain scores; these are a sum of VAS (0-5) for dysmenorrhoea, dyspareunia, non-cyclical pelvic pain, menstrual dyschezia, non-menstrual dyschezia, menstrual backache, non-menstrual backache | |
| Milingos et al. (2006) | POC | ES 1–4 | NS | 1Greek UH | 258 | 101 | 95 | OE:61.8%; USL: 59%; recto-vaginal septum: 10.3% | Minimal and mild: 21.4%; moderate and severe: 71.6% | Prev. LAP: 14.7% | CLET; LT: 6.3% | no | 6 months post-surgery | VAS (10) for each pain type dysmenorrhoea, dyspareunia, non- menstrual pelvic pain. Pain scores grouped as 0, 1-5, 6-7, 8-10 |
|
| Ghai et al. (2020) | RS* | ES 1-4 | NS | 1 UK tertiary EM centre in DGH | 102 | 96 | 100 | ND | Stages 1–3 ‘superficial’: 48%; stage 4 with bowel involvement ‘severe’: 52% | GRA: 6/12 | Stages 1–3: laser destruction or excision; Stage 4: excision (97.1 % CLEP); LT: 2.9% | Severe: yes; superficial: NS | 12 months post-surgery | Pre- and post-operative pain component measured with EPH30 questionnaire | |
*Analysis of data from previous databases (1, 2); †with infiltration of USL or Bladder/intestine/vagina; ‡women with CPP who had laparoscopy; ⁑mean (range).
CLET, complete laparoscopic excisional treatment; DGH, district general hospital; EM, endometriosis; ES, endometrial stage; GRA; gonadotropin receptor antagonist; Hist. confirm., histological confirmation; HT, hormonal treatment; LAP, laparoscopy; LT, laparotomy; ND, not detailed; NS. Not stated; OE, ovarian endometrioma; POC, prospective observational cohort; Prev. previous; ROC, retrospective observational cohort; RS, retrospective secondary; UAH, university affiliated hospital; UH, university hospital.